New Parkinson’s gene is linked to immune system

A hunt throughout the human genome for variants associated with common, late-onset Parkinson’s disease has revealed a new genetic link that implicates the immune system and offers new targets for drug development.

The long-term study involved a global consortium, including Johns Hopkins researchers from the Center for Inherited Disease Research who performed genome-wide association studies on more than 4,000 DNA samples — half from unrelated patients with Parkinson’s and half from healthy “controls.” The team confirmed that a gene in the human leukocyte antigen (HLA) region was strongly linked with Parkinson’s disease; this region contains a large number of genes related to immune system function.

The new data, published August 17 in Nature Genetics, bolster previous studies that hinted about a role for infections, inflammation and autoimmunity in Parkinson’s disease. This genetic finding demonstrates that inflammation isn’t simply a result of having the disease, but somehow is involved as a player in its origin.

“This is an exciting finding from a genome-wide association study (GWAS) which is completely hypothesis-independent and bias-free, based solely on looking at the whole genome and finding out what genes might be related to Parkinson’s,” says Kimberly Doheny, Ph.D., assistant professor, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine; assistant director of the Center for Inherited Disease Research (CIDR); and director of the CIDR Genotyping Lab, Johns Hopkins University.

It was long believed that common, late-onset Parkinson’s had no genetic components — that environmental factors were the exclusive cause. Since genes were first implicated almost two decades ago, Parkinson’s has proven itself a “tough nut to crack,” Doheny says, adding that a handful of GWAS done prior to this one revealed nothing new other than to confirm genes that previously had been found to confer risk.

Setting this GWAS study apart, Doheny says, was the investigators’ meticulous choosing of patients and care of the DNA samples tested. The study’s principal investigator, Haydeh Payami Ph.D., of the New York State Department of Health, describes CIDR’s contribution as “huge.”

It took 18 years to build the study, according to Payami, at whose insistence the collection of DNA and clinical information was standardized using the most rigorous research criteria. Patients from whom samples were taken were tracked for at least a dozen years after their initial diagnoses to assure that they indeed had Parkinson’s, Payami adds, explaining that about 20 percent of PD patients’ diagnoses are actually misdiagnoses.

A neurodegenerative disease affecting between 1 and 2 percent of people over the age of 65, Parkinson’s disease can be difficult to diagnose as no definitive test exists. Its symptoms, which include tremors, sluggish movement, muscle stiffness and difficulty with balance, can be caused by many other things, including other neurological disorders, toxins and even medications.

The GWAS itself took about four months, Doheny says, and cost about $400 per sample tested; whole-genome sequencing costs about $10,000 per sample.

Since 1996, CIDR has provided high-quality genotyping services and statistical genetics consultation to gene hunters: researchers who are working to discover genes that contribute to common diseases by ferreting out variants in the genome. Its role in the Parkinson’s study was to assure that the genotyping dataset was of high quality, that data cleaning was done appropriately and that association analysis was stringent.

“We now have another window into what may be going on in Parkinson’s,” Payami says. “This finding anchors the idea of immune system involvement in genetics and brings it out to the forefront in terms of where research should be directed.”

Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are protective against Parkinson’s disease, according to the study. However, not everyone benefits from them to the same degree. The amount of risk reduction conferred by NSAIDs may vary widely depending on genetic differences, say the researchers. Investigating the connection between Parkinson’s disease and inflammation, especially in the context of the variable genetic make-ups of individuals, likely would lead to better, more selective medicines for treatment.

The study was funded by the National Institute of Neurological Disorders and Stroke, the Michael J Fox Foundation for Parkinson’s Disease Research, the Department of Veterans Affairs, the National Institute on Aging, the National Institute of Mental Health, the Intramural Research Program of the NIH at National Library of Medicine, and the Close to the Cure Foundation.

Authors of the study are Taye H. Hamza, Alain Laederach, Jennifer Montimurro, Dora Yearout, Denise M. Kay, Victoria I. Kusel, Randall Collura and Haydeh Payami, all of the New York State Department of Health; Cyrus P. Zabetian and Ali Samii from the University of Washington, Seattle; lbert Tenesa of the University of Edinburgh, Scotland; Kimberly F Doheny and Elizabeth Pugh, Center for Inherited Disease Research, Johns Hopkins University School of Medicine; John Roberts, Virginia Mason Medical Center; Alida Griffith, Evergreen Hospital Medical Center; William K. Scott, University of Miami; John Nutt, Oregon Health & Sciences University; and Stewart A. Factor, Emory University School of Medicine, Atlanta, GA .

On the Web:

CIDR:
http://www.cidr.jhmi.edu/

Nature Genetics:
http://www.nature.com/ng/index.html

1 COMMENT

  1. Day one.
    I am getting ready to feel the vast feeling of the blackness. Have not told anyone I am going through with this. Spent my time in my lab, eating, sleeping, exercising. Need to continue my work, have little time.

    Day 12
    Continuing to discover new strains. Feel strong in mind. Body is under nourished, but must keep going, cannot eat. Brain activity at 80% 20hours a day.

    Day 40 six.
    Been while since writing anything. Been busy, people feel alien to me. Walk down street in hopes to feel compassion but no such feeling emerges. Brain activity down by 14%. Worried.
    Day 50 two.
    Found it. Found the blackness. Getting ready to inject into self. Expect pain.

    Day 50 three.
    Activity down to 41%. Cannot sleep. Feel like living dead. No strength. Most basic needs a struggle. Feel like soul went. Humanity gone.
    Day 60 four.
    Activity down to 12%. Regret enters mind frequently. Loss of muscle tissue by 24%. Cannot walk for more than five minutes. Body is the prison of mind. Starvation kicked in. Death approaches slowly. Fear enters mind, regret, sadness, anger, hatred.

    Day 60 nine.
    Death is here. I am looking at it. Writing this and watching it takes my soul. A charming encounter. Fear went, hatred and anger left. Regret obsolete.
    Day 70 two.
    Awakened from cold clutches of death. Brain activity rising rapidly. Not using hands to write. Abilities contracted, hatred stronger for each moment. Do not know why. Starting to go blind from it.
    Day 70 three.
    Activity up to 75%. Muscle mass increased by 32%. Strength increased by 400%. Super human brain activity expected. Hatred still growing. Feels good. Hope it grows more. Feelings of greed. Want more. Cannot wait at next day to arrive.
    Day 70 seven.
    Activity up to 125%. Muscle mass increased 3%. Strength increased by 800%. Never felt this dead. This alive. This non human. Death is my master. Hatred is power. Growing. Feel tingle in lips. Dreams about devouring human flesh.
    Day 70 nine.
    Dreams intensifying. Want to taste. Need to taste. Looking for victim. Female. Non missed. Human elements gone. Something else now. Something better. The future.

    Signed
    Steven Jacobs

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.